Procept Biorobotics (PRCT) reported $308M in revenue for fiscal 2025, +37.2% year on year. That ranks #2465 by revenue among 2853 SEC filers and #246 in Healthcare. It posted a net loss of −$95,572 for the same year. Revenue has grown 109.0% a year on average since 2020 ($7.7M then). The fiscal 2025 balance sheet shows $508M in total assets, $287M in cash and $51.6M in long-term debt.
Key figures
| Key figures | FY2025 | YoY | Source |
|---|---|---|---|
| RevenueRevenueFromContractWithCustomerExcludingAssessedTax | $308M | +37.2% | FY20252025-12-31 |
| Gross profitGrossProfit | $196M | +43.1% | FY20252025-12-31 |
| Operating incomeOperatingIncomeLoss | −$104M | −$7.2M | FY20252025-12-31 |
| Net incomeNetIncomeLoss | −$95,572 | −$4,159 | FY20252025-12-31 |
| Operating cash flowNetCashProvidedByUsedInOperatingActivities | −$49.0M | +$50.2M | FY20252025-12-31 |
| Capital expenditurePaymentsToAcquirePropertyPlantAndEquipment | $9.4M | +112.2% | FY20252025-12-31 |
| Total assetsAssets | $508M | −4.9% | FY20252025-12-31 |
| Shareholders' equityStockholdersEquity | $366M | −9.0% | FY20252025-12-31 |
| CashCashAndCashEquivalentsAtCarryingValue | $287M | −14.1% | FY20252025-12-31 |
| Long-term debtLongTermDebtNoncurrent | $51.6M | +0.3% | FY20252025-12-31 |
Revenue is total net sales for the fiscal year, taken from each company's own annual filing.
Reported since the last full year
Three-month figures this company has filed since FY2025. A quarter is not comparable with a full year, and these figures are used nowhere else on the site: not in any ranking, not in comparisons, not in the download.
| Quarter | Revenue | Net income | Source |
|---|---|---|---|
| Q1 20262026-03-31 | $83.1M | −$31.6M | Open → |
| Q2 20262026-06-30 | $94.5M | −$26.9M | Open → |
Only periods that end on a calendar quarter appear here. A company whose fiscal year ends in June files on a different calendar, so it has no row.
Profile
- Legal name
- Procept Biorobotics Corp
- Ticker
- PRCT
- Exchange
- Nasdaq
- SIC classification
- Surgical & Medical Instruments & Apparatus (3841)
- Fiscal year end
- 12-31
- CIK
- 0001588978
Filings
- 10-QAug 5, 2026Open filing →
- 10-QApr 30, 2026Open filing →
- 10-KFeb 26, 2026Open filing →
Similar in size, same sector
| Company | Revenue | Net income |
|---|---|---|
| DocgoDCGO | $322M | −$196M |
| AngiodynamicsANGO | $320M | −$36.7M |
| CormedixCRMD | $312M | $163M |
| Procept BioroboticsPRCT | $308M | −$95,572 |
| BilliontooneBLLN | $305M | $7.5M |
| Skinhealth SystemsSKIN | $301M | −$9.5M |
| EvolusEOLS | $297M | −$51.6M |
Cite this page
Ready-made references for the figures on this page, as published on September 25, 2026.
Wikipedia
{{cite web |title=Procept Biorobotics — Key figures |url=https://companiesranked.com/en/company/procept-biorobotics |website=CompaniesRanked |date=2026-09-25 |language=en}}APA 7
CompaniesRanked. (September 25, 2026). Procept Biorobotics — Key figures. CompaniesRanked. https://companiesranked.com/en/company/procept-bioroboticsBibTeX
@misc{companiesranked-en-company-procept-biorobotics-2026,
author = {{CompaniesRanked}},
title = {{Procept Biorobotics — Key figures}},
year = {2026},
howpublished = {\url{https://companiesranked.com/en/company/procept-biorobotics}},
note = {Compiled from SEC EDGAR XBRL filings; data as of 2026-09-25},
urldate = {2026-09-25}
}The filing itself
The numbers above are read from this document: 10-K · 0001588978-26-000009 · February 26, 2026
{{cite web |title=Procept Biorobotics — Key figures — 10-K (0001588978-26-000009) |url=https://www.sec.gov/Archives/edgar/data/1588978/000158897826000009/prct-20251231.htm |website=SEC EDGAR |publisher=U.S. Securities and Exchange Commission |date=2026-02-26}}The figures are rebuilt with every data refresh, so the reference carries the publication date. Add your own access date if your style requires one.